98%
921
2 minutes
20
Environmental pollution is a major burden of cardiovascular disease. The aim of the study was to investigate the interactions between combined environmental factors and genetic susceptibility on atrial fibrillation (AF) and cardiac structures. The study included 374,495 participants from the UK Biobank, utilizing genetic data and environmental variables (including air pollution, noise, greenspace and water quality). Polygenic risk score (PRS) was calculated to estimate individual genetic risk. Cox proportional hazard model was applied to estimate the impact of exposure factors on the risk of AF occurrence. The mediation analysis was applied to assess the relationship among environmental scores, AF and cardiac structures. Population attributable fraction (PAF) was employed to assess potential influence of mitigating unfavorable environment characteristics on AF. The results showed that the highest group of four domain scores exhibited 3.38-16.83% higher AF risk than the lowest. Individuals with higher scores in four domains and high PRS had hazard ratio (95%CI) of 2.76 (2.62, 2.91), 2.61 (2.47, 2.75), 2.86 (2.71, 3.02) and 2.84 (2.66, 3.02). Environmental factors could indirectly affect cardiac structures through AF. Up to 7.37% of AF cases could be preventable through environmental interventions. Our findings pointed that gene-environment interaction can increase AF risk, which further affect cardiac structures.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12081741 | PMC |
http://dx.doi.org/10.1038/s41598-025-00921-7 | DOI Listing |
J Am Coll Cardiol
August 2025
Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA; Department of Cardiology, Boston Children's Hospital, Boston, Massachusetts, USA.
Trends Mol Med
September 2025
Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Cancer Institute, Cedars-Sinai Medica
Cardiac organoids are 3D self-assembling structures that recapitulate some of the functional, structural, and cellular aspects of the developing heart. Cardiac organoid modeling has overcome many of the limitations of current cardiac modeling systems by providing a human-relevant, multicellular, spatially advanced model that can replicate early key developmental stages of human cardiogenesis. Recent advancements in cardiac organoid modeling have enabled further understanding of cardiogenesis, cardiovascular disease, and drug-induced cardiotoxicity.
View Article and Find Full Text PDFCardiovasc Revasc Med
August 2025
Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA. Electronic address:
Secondary mitral regurgitation (SMR) remains a prevalent and challenging complication in patients with heart failure (HF), associated with poor prognosis despite optimal guideline-directed medical therapy (GDMT) and cardiac resynchronization therapy. Current American and European guidelines recommend GDMT as first-line therapy, with transcatheter edge-to-edge repair (TEER) reserved for severe symptomatic SMR patients who remain refractory. However, both guidelines preceded the reporting of pivotal randomized controlled trials (RESHAPE-HF2, MATTERHORN, and EFFORT) and emerging evidence in new clinical scenarios.
View Article and Find Full Text PDFRev Esp Cardiol (Engl Ed)
September 2025
Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, España; Servicio de Cardiología, Hospital Clínico de Santiago de Compostela, Santiago de Compostela, España.
Introduction And Objectives: This report presents the 2024 activity data from the Interventional Cardiology Association of the Spanish Society of Cardiology (ACI-SEC).
Methods: All interventional cardiology laboratories in Spain were invited to complete an online survey. Data analysis was conducted by an external company and then reviewed and presented by the ACI-SEC board.
J Mol Cell Cardiol
September 2025
Cardiovascular Research Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address:
Selective therapeutic targeting of cardiomyocytes (CMs) and non-myocytes (NMs) within the heart is an active field of research. The success of those novel therapeutic strategies is linked to the ability to accurately assess uptake and gene delivery efficiencies in clinically relevant animal models. Nevertheless, quantification at the single cell level remains a significant challenge.
View Article and Find Full Text PDF